Patients in intensive care units often face a scary reality when they get pneumonia while on a breathing machine. This infection can be hard to clear because the drugs struggle to reach the lungs effectively. A large review looked at adding inhaled antibiotics to standard treatment to see if it made a difference for these vulnerable people. The analysis included data from 1,425 patients who received a placebo or blank treatment versus those who got the inhaled drug.
The results were clear for those who needed the extra help. People who received the inhaled antibiotics had a significantly higher chance of clinical cure compared to those who did not. The review also found that adding this treatment reduced the risk of death from any cause. For patients with only ventilator-associated pneumonia, the cure rate jumped even higher, and the risk of dying dropped further.
Safety was another major concern for doctors and families. The data showed that the inhaled antibiotics helped clear the infection from the lungs better than the placebo. Surprisingly, the treatment also reduced the chance of new drug resistance developing. When compared to intravenous antibiotics, the inhaled version shortened the time patients needed the breathing machine and lowered kidney toxicity risks. However, some comparisons had limited data, so doctors should wait for more high-quality trials before changing standard practices.
